127 related articles for article (PubMed ID: 31378535)
1. Longitudinal quantification of adenovirus neutralizing responses in Zambian mother-infant pairs: Impact of HIV-1 infection and its treatment.
Privatt SR; Bullard BL; Weaver EA; Wood C; West JT
Vaccine; 2019 Aug; 37(36):5177-5184. PubMed ID: 31378535
[TBL] [Abstract][Full Text] [Related]
2. Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.
Hrycak CP; Windmann S; Bayer W
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375593
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of serum neutralizing antibodies to adenovirus type 5 (Ad5) and 41 (Ad41) in children is associated with age and sanitary conditions.
Yang WX; Zou XH; Jiang SY; Lu NN; Han M; Zhao JH; Guo XJ; Zhao SC; Lu ZZ
Vaccine; 2016 Nov; 34(46):5579-5586. PubMed ID: 27682509
[TBL] [Abstract][Full Text] [Related]
4. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
5. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations.
Barouch DH; Kik SV; Weverling GJ; Dilan R; King SL; Maxfield LF; Clark S; Ng'ang'a D; Brandariz KL; Abbink P; Sinangil F; de Bruyn G; Gray GE; Roux S; Bekker LG; Dilraj A; Kibuuka H; Robb ML; Michael NL; Anzala O; Amornkul PN; Gilmour J; Hural J; Buchbinder SP; Seaman MS; Dolin R; Baden LR; Carville A; Mansfield KG; Pau MG; Goudsmit J
Vaccine; 2011 Jul; 29(32):5203-9. PubMed ID: 21619905
[TBL] [Abstract][Full Text] [Related]
6. A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55.
Tian X; Jiang Z; Fan Y; Qiu S; Zhang L; Li X; Zhou Z; Liu T; Ma Q; Lu X; Zhong B; Zhou R
Antiviral Res; 2018 Jun; 154():17-25. PubMed ID: 29626491
[TBL] [Abstract][Full Text] [Related]
7. Adenovirus type 4 and 7 vaccination or adenovirus type 4 respiratory infection elicits minimal cross-reactive antibody responses to nonhuman adenovirus vaccine vectors.
Paris R; Kuschner RA; Binn L; Thomas SJ; Colloca S; Nicosia A; Cortese R; Bailer RT; Sullivan N; Koup RA
Clin Vaccine Immunol; 2014 May; 21(5):783-6. PubMed ID: 24623627
[TBL] [Abstract][Full Text] [Related]
8. CD40 Ligand and GMCSF Coexpression Enhance the Immune Responses and Protective Efficacy of PCV2 Adenovirus Vaccine.
Li D; Huang Y; Du Q; Wang Z; Chang L; Zhao X; Tong D
Viral Immunol; 2016 Apr; 29(3):148-58. PubMed ID: 26982652
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.
Barouch DH; Pau MG; Custers JH; Koudstaal W; Kostense S; Havenga MJ; Truitt DM; Sumida SM; Kishko MG; Arthur JC; Korioth-Schmitz B; Newberg MH; Gorgone DA; Lifton MA; Panicali DL; Nabel GJ; Letvin NL; Goudsmit J
J Immunol; 2004 May; 172(10):6290-7. PubMed ID: 15128818
[TBL] [Abstract][Full Text] [Related]
10. Oral Vaccination with Replication-Competent Adenovirus in Mice Reveals Dissemination of the Viral Vaccine beyond the Gastrointestinal Tract.
Goffin E; Javaux J; Destexhe E; Pretto CD; Spindler KR; Machiels B; Gillet L
J Virol; 2019 Jul; 93(13):. PubMed ID: 30996103
[TBL] [Abstract][Full Text] [Related]
11. Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant Morbidity.
Ghulam-Smith M; Olson A; White LF; Chasela CS; Ellington SR; Kourtis AP; Jamieson DJ; Tegha G; van der Horst CM; Sagar M
mBio; 2017 Oct; 8(5):. PubMed ID: 29066544
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.
Li Q; Liu Q; Huang W; Song A; Zhao C; Wu J; Wang Y
Hum Vaccin Immunother; 2017 Jun; 13(6):1-8. PubMed ID: 28301274
[TBL] [Abstract][Full Text] [Related]
13. Serological immunity to adenovirus serotype 5 is not associated with risk of HIV infection: a case-control study.
Curlin ME; Cassis-Ghavami F; Magaret AS; Spies GA; Duerr A; Celum CL; Sanchez JL; Margolick JB; Detels R; McElrath MJ; Corey L
AIDS; 2011 Jan; 25(2):153-8. PubMed ID: 21150554
[TBL] [Abstract][Full Text] [Related]
14. Neutralizing antibodies to human and simian adenoviruses in humans and New-World monkeys.
Ersching J; Hernandez MI; Cezarotto FS; Ferreira JD; Martins AB; Switzer WM; Xiang Z; Ertl HC; Zanetti CR; Pinto AR
Virology; 2010 Nov; 407(1):1-6. PubMed ID: 20797754
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of ad5 vaccine immunity and toxicity: fiber shaft targeting of dendritic cells.
Cheng C; Gall JG; Kong WP; Sheets RL; Gomez PL; King CR; Nabel GJ
PLoS Pathog; 2007 Feb; 3(2):e25. PubMed ID: 17319743
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of adenovirus vaccines expressing the PCV2 capsid protein in pigs.
Li D; Du Q; Wu B; Li J; Chang L; Zhao X; Huang Y; Tong D
Vaccine; 2017 Aug; 35(36):4722-4729. PubMed ID: 28755834
[TBL] [Abstract][Full Text] [Related]
17. [Anti-adenovirus neutralizing antibodies and Gag-specific cellular immune responses in Macaca fascicularis immunized with Ad5-HIVgag].
Li Y; Yang L; Yang L; Chen DY; Feng X; Yu SQ; Li ZL; Zeng Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Dec; 25(6):413-5. PubMed ID: 22734222
[TBL] [Abstract][Full Text] [Related]
18. Trimeric knob protein specifically distinguishes neutralizing antibodies to different human adenovirus species: potential application for adenovirus seroepidemiology.
Yu B; Dong J; Wang C; Wang Z; Gao L; Zhang H; Wu J; Kong W; Yu X
J Gen Virol; 2014 Jul; 95(Pt 7):1564-1573. PubMed ID: 24764358
[TBL] [Abstract][Full Text] [Related]
19. Maternal Binding and Neutralizing IgG Responses Targeting the C-Terminal Region of the V3 Loop Are Predictive of Reduced Peripartum HIV-1 Transmission Risk.
Martinez DR; Vandergrift N; Douglas AO; McGuire E; Bainbridge J; Nicely NI; Montefiori DC; Tomaras GD; Fouda GG; Permar SR
J Virol; 2017 May; 91(9):. PubMed ID: 28202762
[TBL] [Abstract][Full Text] [Related]
20. Reduced Poliovirus vaccine neutralising-antibody titres in infants with maternal HIV-exposure.
Sanz-Ramos M; Manno D; Kapambwe M; Ndumba I; Musonda KG; Bates M; Chibumbya J; Siame J; Monze M; Filteau S; Gompels UA;
Vaccine; 2013 Apr; 31(16):2042-9. PubMed ID: 23474309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
